Phase 3 study finds fezolinetant reduces the frequency and severity of menopausal hot flashes
by The Endocrine SocietyCredit: Pixabay/CC0 Public DomainFezolinetant significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, associated w
Updated on: February 03,2024
13
Phase 3 study finds fezolinetant reduces the frequency and severity of menopausal hot flashes
by The Endocrine SocietyCredit: Pixabay/CC0 Public DomainFezolinetant significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, associated w
Updated on:February 03,2024
13